Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors. Jotanovic J, Boldt HB, Burton M, Andersen MS, et al. Acta Neuropathol 2024;148:68.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jotanovic J, Boldt HB, Burton M, Andersen MS, et al. Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors. Acta Neuropathol 2024;148:68.
PMID: 39580368